Management of pT1G3 Bladder Cancer

European Urology, Supplements

Volumn 10, Issue 3, 2011, Pages

  Thalmann, George N ^a   Birkhäuser, Frédéric ^a   Roth, Beat ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

BCG; Cystectomy; Non muscle invasive bladder cancer; TURBT

Indexed keywords

BLADDER CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL FEATURE; COUNSELING; CYSTECTOMY; HUMAN; LYMPH NODE DISSECTION; ORGAN PRESERVATION; OUTCOME ASSESSMENT; PATIENT SELECTION; PELVIS LYMPH NODE; PRIORITY JOURNAL; RADICAL RESECTION; REVIEW; RISK FACTOR; STRATIFIED SAMPLE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 79955970509     PISSN: 15699056     EISSN: 18781500     Source Type: Journal    
DOI: 10.1016/j.eursup.2011.03.002     Document Type: Review

References (26)

1. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010, 57:60-70.
2. Van der Meijden A., Sylvester R., Collette L., Bono A., Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer trials. J Urol 2000, 164:1533-1537.
3. Ghoneim M.A., el-Mekresh M.M., el-Baz M.A., el-Attar I.A., Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1,026 cases. J Urol 1997, 158:393-399.
4. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 2008, 53:146-152.
5. Grimm M.O., Steinhoff C., Simon X., Spiegelhalder P., Ackermann R., Vogeli T.A. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003, 170:433-437.
6. Brauers A., Buettner R., Jackse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol 2001, 165:808-810.
7. Herr H., Dalbagni G. Presence and absence of tumor after BCG therapy. J Urol 2003, 169:1706-1708.
8. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999, 162:74-76.
9. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 2002, 41:523-531.
10. Stanislaus P., Zaak D., Stadler T., et al. Photodynamic diagnosis in patients with T1G3 bladder cancer: influence on recurrence rate. World J Urol 2010, 28:407-411.
11. Sylvester R.J., Oosterlinck W., van der Meijden A.P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a metaanalysis of published results of randomized clinical trials. J Urol 2004, 171:2186-2190.
12. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003, 169:96-100.
13. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 2004, 172:70-75.
14. Birkmeyer J.D., Siewers A.E., Finlayson E.V., et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002, 346:1128-1137.
15. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
16. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003, 21:690-696.
17. Hautmann R.E., Gschwend J.E., de Petriconi R.C., Kron M., Volkmer B.G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006, 176:486-492.
18. Ong C.H., Schmitt M., Thalmann G.N., Studer U.E. Individualized seminal vesicle sparing cystoprostatectomy combined with ileal orthotopic bladder substitution achieves good functional results. J Urol 2010, 183:1337-1341.
19. Cheng L., Neumann R.M., Weaver A.L., Spotts B.E., Bostwick D.G. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 1999, 17:3182-3187.
20. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol 2007, 51:152-160.
21. Brake M., Loertzer H., Horsch R., Keller H. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000, 163:1697-1701.
22. Herr H.W., Badalament R.A., Amato D.A., Laudone V.P., Fair W.R., Whitmore W.F. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol 1989, 141:22-29.
23. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 2000, 164:685-689.
24. Herr H.W. Tumor progression and survival in patients with T1G3 bladder tumors: 15-year outcome. Br J Urol 1997, 80:762-765.
25. Soloway M.S., Sofer M., Vaidya A. Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 2002, 167:1573-1583.
26. Raj G.V., Herr H., Serio A.M., et al. Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer. J Urol 2007, 177:1283-1286.